J0675 Carboprost Injection HCPCS Reimbursement

HCPCS Level II code J0675 designates a 0.1 mg injection of carboprost tromethamine, an injectable uterotonic used in obstetric care. Nationally, this medication code matters for hospitals and outpatient facilities that manage postpartum hemorrhage and other indications requiring prostaglandin therapy, where effective tracking of medication use, billing, and coverage is important for clinical workflows and payer reimbursement.

This analysis covers coverage and payment contexts for major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing benchmarks, common payer considerations, and clinical context tied to use of carboprost tromethamine in acute obstetric settings. The report also outlines typical sites of service, common modifiers seen on service lines, and where available, associated coding considerations.

The publication provides practical reference material for revenue cycle and clinical teams: what J0675 represents, how it is commonly billed across inpatient and outpatient settings, and key areas to watch in payer policies and authorization practices. Data not provided in the input are noted where applicable.

Billing Code Overview

HCPCS Level II code J0675 represents an injection of carboprost tromethamine, 0.1 mg. This code denotes a single unit of the medication formulation used for obstetric and gynecologic indications where carboprost is clinically indicated.

Service type: Medication administration (injectable prostaglandin analog)
Typical site of service: Hospital inpatient, hospital outpatient, labor and delivery unit, and ambulatory surgery or procedure areas where injectable uterotonic therapy is given.

Data not available in the input.

Clinical Context

A 28-year-old pregnant patient at 39 weeks' gestation experiences postpartum hemorrhage due to uterine atony immediately following vaginal delivery. After initial uterotonic therapy with oxytocin and uterine massage proves inadequate, the obstetric team prepares and administers J0675 (injection, carboprost tromethamine, 0.1 mg) intramuscularly or intramyometrially. The clinical workflow includes rapid assessment of hemodynamic status, establishment of intravenous access, continuous monitoring of vital signs, documentation of estimated blood loss, consent discussion when feasible, preparation of the carboprost syringe per manufacturer instructions, administration in divided doses up to the recommended total, and observation for expected pharmacologic effects and adverse reactions (e.g., bronchospasm, hypertension, fever, vomiting, diarrhea). If bleeding persists, escalation includes additional uterotonics, intrauterine balloon tamponade, surgical interventions, or blood transfusion as clinically indicated. Documentation captures indication, dose and route, time of administration, patient response, and any adjunctive procedures or medications used.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when work or resources for controlling hemorrhage are substantially greater than usual for carboprost administration (document specific reasons).

Taxonomy Code	Specialty	Notes
`207P00000X`	Obstetrics & Gynecology	Primary specialty administering carboprost for postpartum hemorrhage.
`207L00000X`	Maternal-Fetal Medicine	Specialists managing high-risk obstetric hemorrhage and complex cases.
`163W00000X`	Anesthesiology	Provides airway and hemodynamic support during hemorrhage and anesthesia for operative interventions.
`208000000X`	Family Medicine	May manage uncomplicated deliveries and initial postpartum hemorrhage in certain settings.
`226E00000X`	Nursing (Certified Registered Nurse Anesthetist)	Provides anesthesia services where applicable and is associated with `QX` modifier scenarios.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`O72.0`	Third-stage hemorrhage	Directly relevant: carboprost is indicated for postpartum hemorrhage due to uterine atony occurring in the third stage.
`O72.1`	Delayed and secondary postpartum hemorrhage	Carboprost may be used when bleeding persists or recurs after initial control measures.
`O72.2`	Other immediate postpartum hemorrhage	Covers other causes of immediate postpartum bleeding where carboprost can be part of medical management.
`O72.3`	Retained placenta, causing hemorrhage	Carboprost may be used adjunctively while preparing for manual removal or surgical management.
`O72.4`	Hemorrhage following abortion and ectopic and molar pregnancy	Carboprost can be used in certain uterotonic protocols when indicated for hemorrhage in these contexts.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`59409`	Delivery of placenta (separate procedure)	May be performed in the immediate postpartum period; carboprost administration often occurs after delivery of the placenta for uterine atony.
`59610`	Vaginal delivery only (with or without episiotomy and/or forceps)	Represents the global obstetric delivery encounter during which postpartum hemorrhage and carboprost administration may occur.
`59120`	Postpartum hemorrhage management, requiring additional procedures (e.g., exploration of uterus)	Used when surgical management is required in addition to pharmacologic uterotonics like carboprost.
`36000`	Introduction of needle or catheter into vein (for IV access)	IV access is commonly obtained for fluid resuscitation and medication administration when managing hemorrhage.
`36600`	Arterial catheterization for monitoring	May be used for invasive hemodynamic monitoring in severe hemorrhage cases requiring intensive management.

OpenPayer

Summary & Overview

HCPCS Level II J0675: Injection, carboprost tromethamine 0.1 mg